LONDON, Sept. 16, 2015 /PRNewswire/ --
Several people across the globe suffer from different neurological disorders. However, the drugs currently available in the market provide only symptomatic relief and do not treat the root cause. This is because of their inability to penetrate across the blood brain barrier (BBB). BBB is a highly selective permeable membrane which allows the entry of only specific molecules, across it, into the brain. The widening gap between the demand of effective treatments and supply of BBB permeable drugs is going to provide a major impetus to the BBB market in the coming decade. Several pharma companies have identified the unmet need and have developed proprietary technologies. These technologies cater to the aforementioned concerns and are being deployed to develop drugs and APIs that penetrate across the barrier and reach the brain at therapeutically active amounts. Once approved, these drugs are likely to park a major share of the total market.
With growing advances in R&D, and the increasing demands for specific drugs, BBB technologies have become one of the key focus areas of researchers and companies across the world. Several venture capital firms have backed the start-ups working in this field. In addition, partnerships and collaborations have played a pivotal role in the advancement of this market. Many smaller companies, as a part of their business model, are looking to out-license their technologies to the established players in this industry.
SCOPE OF THE REPORT
The 'BBB Technologies: Novel CNS Drug Delivery Approaches, 2015 - 2030' report provides an extensive study of the emerging market of BBB technologies and associated drugs for neurologic diseases. The focus of this study is primarily on the technologies that are non-invasive in nature. There are other technologies which either disrupt the barrier or use an alternate route to bypass it. These technologies are, for the purpose of this report, considered competing in nature. The report covers various aspects such as research pipeline, technological profiles, recent developments and sales forecast to assess new evolving opportunities. We have also provided a competitive market analysis to compare the potential that resides in the leading neurological indications, such as Parkinson's disease, Alzheimer's disease, multiple sclerosis and brain cancer, for which BBB permeable drugs are being developed.
In addition to the well-known technologies, we have also provided case studies on four other technologies; these are either in direct competition or have been previously worked upon. Our opinion and insights, presented in this study, were influenced by the discussions that we conducted with different technology providers in this industry.
One of the key objectives of this report is to understand the future state of the BBB technologies market. This is done by analyzing the following:
- Pipeline candidates based on these technologies
- Size of target consumer segments
- Expected launch year and countries where these clinical stage candidates are likely to receive commercialization rights
-Likely price points
The base year for the report is 2014. The report provides market forecasts for the period 2019 - 2030. The figures mentioned in this report are in USD, unless otherwise specified.
Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Other analysts' opinion reports
While the focus has been on forecasting the market over the coming nine years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
Chapter 2 provides an executive summary of the insights captured in our research. It offers a high level view on the current scenario of the market of BBB technologies and the likely mid-long term evolution.
Chapter 3 provides a general overview of the central nervous system. It talks about the structure of blood brain barrier, its functions, historical evolution and recent milestones. We have covered, in detail, different methods of CNS drug delivery. The chapter also outlines several strategies that have been worked upon to transport the drugs and therapeutics across the barrier. In addition, the limitations of CNS drug delivery are also highlighted in this chapter.
Chapter 4provides the list of technology developers who have developed proprietary BBB technologies. Itoffers an extensive pipeline of all the drugs that are being developed by deploying these technologies.The pipeline analysis includes information on the phase of development, nature of drugs, targeted indications etc. We have also covered details of additional drugs which are able to penetrate the BBB but are not based on any underlying technology.
Chapter 5 offers an insightful discussion onsix most popular indications targeted by the BBB permeable drugs under development. This analysis revolves around current landscape, prevailing competition, anticipated shift in the market trend and the key focus for the future.
Chapter 6 covers, in detail, the underlying strategies based on which BBB technologies have been devised. These include receptor mediated transcytosis (RMT), increasing permeability and passive diffusion approach. Within RMT, we have provided the details of bispecific antibodies approach and trojan horse mediated delivery either by direct coupling or by using nano-carriers.
Chapter 7 provides detailed profiles of all the BBB proprietary platforms, based on aforementioned strategies, under development by different technology developers. These profiles include details of the technology, a brief company overview,relevant partnerships and fundings received by the company, related recent developments and milestones, history of development and associated patents (wherever details were available).
Chapter 8 provides case studies on four technologies (Intrathecal drug delivery platform, TTP technology, BioMarin technology platform and NeuroTrans technology) outlining their unique technology / platform features.
Chapter 9 presents a scenario based approach to identify the future evolution of the industry. Given the uncertainty surrounding the adoption rates, we have done a multivariate sensitivity analysis to present different tracks of industry's evolution.
Chapter 10 is a collection of transcripts based on our discussion with some of the upcoming players in the industry such as Ossianix, biOasis, and Sagetis Biotech.
Chapter 11 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and a brief description of some of the emerging technologies that are expected to invade the market in future.
Chapters 12 and 13 are appendices, which provide the list of companies and tabulated data for all the figures presented in the report.
1. More than 25 companies have developed proprietary non-invasive BBB technologies. Majority of these companies are either university spin-offs or start-up firms. Some pharma giants, such as Roche, AbbVie and Genzyme, have also deployed their expertise to develop novel technology platforms.
2. Majority of BBB technologies (53%) are based on the process of receptor mediated transcytosis (RMT). Within RMT, Trojan horse is the most common strategy. Several companies, such as Vect-Horus, BBB Therapeutics, and Angiochem, have utilized this approach to transport therapeutics into the brain.
3. These technology developers are evaluating their technologies on over 50 drug candidates spread across different development stages. 80% of these drugs are undergoing either preclinical or proof of concept and efficacy studies.
4. Based on several parameters, such as target patient population, and competition (both in terms of number of pipeline and marketed drugs), we believe that indications such as Alzheimer's disease, epilepsy, and Parkinson's disease offer a very lucrative future for this market.
5. Interest of venture capital firms, licensing/ partnership opportunities will continue to act as key growth drivers of BBB technologies market. In fact, during our research, we identified several instances where venture capitalists and other strategic investors have actively supported the research efforts.
6. The first batch of BBB permeable drugs,based on these technologies, is anticipated to be launched in 2019/2020; post this, we expect the momentum to rise steadily trending towards a multi-billion dollar market by 2030.
Download the full report: https://www.reportbuyer.com/product/2997633/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers